Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT00096018
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 10
- Registration Number
- NCT00090870
- Locations
- 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT00089609
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
- Conditions
- Interventions
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00089544
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
- Conditions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00089167
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00003894
- Locations
- 🇺🇸
Louisiana State University School of Medicine, New Orleans, Louisiana, United States
🇺🇸Brooke Army Medical Center, Fort Sam Houston, Texas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 500
- Registration Number
- NCT00083876
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 190
- Registration Number
- NCT00083902
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
- Conditions
- Interventions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 97
- Registration Number
- NCT00083915
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00003850
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.